A Multi-Center, Open Label, Expanded Access Trial Of Maraviroc
Phase of Trial: Phase III
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Expanded access
- Sponsors Pfizer; ViiV Healthcare
- 10 Jun 2017 Biomarkers information updated
- 02 Aug 2011 New source identified and integrated (European Clnincal Trials Database).
- 01 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.